Cel Sci Corp (CVM) Stock Price & Analysis
Cel Sci Corp (CVM) fell 0.84% to USD 1.18 as of July 25, 2026 at 16:27 UTC, according to Nexqual real-time market data.
CVM last closed at USD 1.19; the session ranged USD 1.16–1.22 on volume of 142,262 shares. Market capitalization is $20.62M, with a 52-week range of USD 0.89–13.48 (ASE). Source: Nexqual, July 25, 2026 at 16:27 UTC.
Key Statistics (as of July 25, 2026 at 16:27 UTC)
| Price | USD 1.18 |
|---|---|
| Change | ▼ 0.84% (down) |
| Previous Close | USD 1.19 |
| Open | USD 1.22 |
| Day Range | USD 1.16 – 1.22 |
| 52-Week Range | USD 0.89 – 13.48 |
| Volume | 142,262 shares |
| Market Cap | $20.62M |
| Exchange | ASE |
Technical Analysis (CVM)
Nexqual's technical model rates CVM "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 16:27 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.62 (neutral) |
| vs SMA50 | Below (USD 1.26) |
| MACD | -0.03 (negative) |
Analyst Ratings (CVM)
Wall Street analysts rate CVM "Buy" based on 1 analysts, with a mean price target of USD 15 (range USD 15–15), per Nexqual as of July 25, 2026 at 16:27 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 15 |
| High Target | USD 15 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CVM)
Source: Nexqual, July 25, 2026 at 16:27 UTC.
Financials & Fundamentals (CVM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -305.27% |
| Debt / Equity | 123.82 |
| Current Ratio | 0.6 |
| Total Cash | $1.90M |
| Total Debt | $8.51M |
| Free Cash Flow | $-9.23M |
Source: Nexqual, July 25, 2026 at 16:27 UTC.
Financial Health Score (CVM)
Nexqual rates Cel Sci Corp's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 16:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $2M cash vs $9M debt |
| Cash Flow | Weak — Operating cash flow -$17M |
| Efficiency | Critical — ROE -305%, ROA -70.3% |
Ownership (CVM)
| Insider Ownership | +6.31% |
|---|---|
| Institutional Ownership | +4.50% |
| Shares Outstanding | 17.48M |
| Float | 8.22M |
| Short % of Float | +4.24% |
Source: Nexqual, July 25, 2026 at 16:27 UTC.
Leadership (CVM)
Cel Sci Corp is led by Geert R. Kersten (age 66), CEO, CAO,Treasurer and Director, per Nexqual as of July 25, 2026 at 16:27 UTC.
| CEO, CAO,Treasurer and Director | Geert R. Kersten (age 66) |
|---|---|
| Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary | Patricia B. Prichep (age 74) |
| Chief Scientific Officer | Eyal Talor (age 69) |
| Senior Vice President of Regulatory Affairs | John Cipriano (age 83) |
Major Backers & Investors (CVM)
Notable institutional backers of Cel Sci Corp include MAI Capital Management, Fidelity, Bank of America Corporation, according to Nexqual as of July 25, 2026 at 16:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MAI Capital Management | 0.52% |
| Fidelity | 0.38% |
| Bank of America Corporation | 0.23% |
| Renaissance Technologies | 0.21% |
| US BANCORP \DE\ | 0.17% |
| Xtx Topco Ltd | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.06% |
| Geode Capital | 0.49% |
| BlackRock | 0.25% |
| State Street | 0.16% |
Source: Nexqual, July 25, 2026 at 16:27 UTC.
From Cel Sci Corp's Latest SEC 10-K Filing (filed 2025-12-29)
Key Strengths & Strategy (as disclosed to the SEC)
- CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
- The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
- It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.
- In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments.
Partnerships
- CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AGEN | Agenus Inc. | USD 5.98 | ▲ 8.14% |
| BGMSP | Bio Green Med Solution Inc. | USD 3.5 | ▲ 0% |
| CSCID | COSCIENS Biopharma Inc | USD 5.5 | ▲ 1.85% |
| CRIS | Curis, Inc. | USD 4.89 | ▼ 1.01% |
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 9.34 | ▼ 1.79% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 16:27 UTC. This page is informational and not investment advice.